Small Molecules

27 Jun 2019 SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma
27 Jun 2019 Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis
27 Jun 2019 Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
27 Jun 2019 TARIS Announces Positive Results of Phase 1b Trial of TAR-200 in Muscle Invasive Bladder Cancer
27 Jun 2019 X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome
25 Jun 2019 Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
25 Jun 2019 Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients
25 Jun 2019 Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial
25 Jun 2019 BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea
25 Jun 2019 Intensity Therapeutics Announces Clinical Collaboration with Merck
25 Jun 2019 Imbrium Therapeutics Advances Insomnia Pipeline Through Initiation of a Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation
25 Jun 2019 Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis
25 Jun 2019 Rodin Therapeutics Announces Positive Phase 1 Results Supporting Continued Development of RDN-929 for Treatment of Neurologic Diseases
25 Jun 2019 Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis
25 Jun 2019 U.S. Food and Drug Administration accepts GSK’s application for ZEJULA (niraparib) in late stage ovarian cancer with priority review
24 Jun 2019 Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
24 Jun 2019 Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia
24 Jun 2019 Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
24 Jun 2019 Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
24 Jun 2019 Asieris Announces Completion of Enrollment for its US APL-1202 Phase Ib Clinical Trial
24 Jun 2019 AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality
24 Jun 2019 Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
22 Jun 2019 Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
22 Jun 2019 European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
22 Jun 2019 FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up